sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group, Inc.: Disclosure on Avadel Pharmaceuticals plc
The Vanguard Group, Inc. has disclosed its interest in Avadel Pharmaceuticals plc, confirming the ownership and control of 5,527,806 ordinary shares, representing 5.68% of the company's shares. These details were submitted under Form 8.3 concerning regulations by the Irish Takeover Panel.
The disclosure shows a recent purchase of 665 ordinary shares at a price of 23.02 USD per unit. This activity reflects Vanguard's strategy in managing its interests within Avadel Pharmaceuticals.
No additional derivatives, options, or agreements affecting the securities have been reported. Similarly, there are no indemnities or arrangements inducing dealing activity, ensuring transparency in the declaration process.
Vanguard's latest position showcases its significant stake in Avadel, marking a continued commitment to its investment strategy.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.